Investigation of patients with unclassified bleeding disorder and abnormal thrombin generation for physiological coagulation inhibitors reveals multiple abnormalities and a subset of patients with increased tissue factor pathway inhibitor activity
- 31 January 2020
- journal article
- research article
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 42 (3), 246-255
- https://doi.org/10.1111/ijlh.13155
Abstract
Introduction We have routinely used thrombin generation to investigate patients with unclassified bleeding disorder (UBD). Aims: To investigate haemostatic abnormalities in patients with UBD that had abnormal thrombin generation on at least one occasion. Methods Investigation of 13 known UBD patients with thrombin generation and detailed haemostatic testing was undertaken including TFPI assays but also thrombomodulin and fibrinogen‐γ. Results 12 females and 1 male were included. No patient had a platelet function disorder or coagulation factor deficiency that explained the bleeding phenotype, though 2 patients had factor deficiencies; a factor X of 0.41 IU/mL and a factor XI of 0.51 IU/mL. ThromboGenomics revealed variants for these factors but no other abnormalities. Patients were included who previously had either prolonged lag time or decreased endogenous thrombin potential (ETP) via high dose tissue factor (5 pmol/L) or low dose tissue factor (1.5 pmol/L) with corn trypsin inhibitor (CTI). Tissue factor pathway inhibitor (TFPI) activity was significantly increased (P < .001; increased in 8 patients) compared with controls and abnormalities in soluble thrombomodulin (2 patients), fibrinogen‐γ (1 patient) and tPA (4 patients for each) were seen. Total and free TFPI levels were not increased. Mixing studies of patient plasma with 50:50 normal plasma for thrombin generation via low dose tissue factor failed to correct the ETP consistent with ongoing inhibition. Addition of an anti‐TFPI antibody partially corrected thrombin generation to normal levels. TFPI sequencing was unremarkable. Conclusion TFPI activity may be increased in a subset of UBD patients. Further research studies are warranted in UBD patients for coagulation inhibitor abnormalities.Keywords
Funding Information
- British Society for Haematology (Early‐Stage Research Start‐up Grant)
This publication has 38 references indexed in Scilit:
- Coagulation factor VA2440G causes east Texas bleeding disorder via TFPIαJCI Insight, 2013
- Inhibition of thrombin‐mediated factor V activation contributes to the anticoagulant activity of fibrinogen γ′Journal of Thrombosis and Haemostasis, 2013
- Prospective evaluation of the clinical utility of quantitative bleeding severity assessment in patients referred for hemostatic evaluationJournal of Thrombosis and Haemostasis, 2011
- The power of a standardized bleeding score in diagnosing paediatric type 1 von Willebrand’s disease and platelet function defectsHaemophilia, 2010
- Regulation of TFPI function by protein SJournal of Thrombosis and Haemostasis, 2009
- Generation and validation of the Condensed MCMDM‐1VWD Bleeding Questionnaire for von Willebrand diseaseJournal of Thrombosis and Haemostasis, 2008
- Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiencyBlood, 2008
- Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitorJournal of Thrombosis and Haemostasis, 2008
- Evaluation of low PAI‐1 activity as a risk factor for hemorrhagic diathesisJournal of Thrombosis and Haemostasis, 2006
- Tissue Factor Pathway Inhibitor Activity in Human PlasmaArteriosclerosis, Thrombosis, and Vascular Biology, 1995